Hidehito HORINOUCHI
LightNews LightNews
banner
hhorinouchi.bsky.social
Hidehito HORINOUCHI
@hhorinouchi.bsky.social
120 followers 36 following 91 posts
Medical Oncologist, NCC Japan, JCOG Lung Cancer Study Group, Education committee of JSMO, JLCS, @iaslc.bsky.social. @ascocancer.bsky.social FCOI http://bit.ly/3DBhVGE
Posts Replies Media Videos
hhorinouchi.bsky.social
🔥Oncology HERE & NOW Webcast/Podcast🆙
🚨 @realbowtiedoc.bsky.social & @crisbergerot.bsky.social
🎯 #SupportiveCare , the future of #Telemedicine
✅Japanese🇯🇵captions are available in #Youtube
youtu.be/4WYdTostU7w?...
@oncoalert.bsky.social
buzzsprout.com/1324033/epis...
March 30, 2025 at 10:11 AM
hhorinouchi.bsky.social
⏰NOW OUT‼️#ELCC25
🔥COCOON🦋: Preventing Moderate to Severe Dermatologic Adverse Events in 1st-line EGFR-mutant Advanced NSCLC Treated with Amivantamab + Lazertinib
🎙️ Dr. Nicolas Girard
🎯AEs ≥G2: OR 0.19 (95%CI, 0.09–0.40)
✅NCT06120140
#LCSM
@oncoalert.bsky.social
@myesmo.bsky.social
@iaslc.bsky.social
March 29, 2025 at 4:06 PM
hhorinouchi.bsky.social
⏰NOW OUT‼️ #ELCC25
🔥MARIPOSA🦋: Amivantamab plus lazertinib vs osimertinib in 1L EGFRm advanced NSCLC: Final OS
🎙️Prof. James Yang
🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎯Seems like extending the OS for 1️⃣2️⃣ months
✅NCT04487080
#LCSM #EGFR
@oncoalert.bsky.social
@myesmo.bsky.social
@iaslc.bsky.social
March 26, 2025 at 5:27 PM
Reposted by Hidehito HORINOUCHI
vslim.bsky.social
In January 2025, we joined Taiwan Association for the Study of Lung Cancer (TASLC) in running a reviewer workshop in Taipei. 20 selected participants from Taiwan, Malaysia, Thailand, South Korea & Japan attended the workshop. Thanks TASLC for organizing and support! @jtoonline.bsky.social
March 23, 2025 at 2:35 PM
hhorinouchi.bsky.social
🔥 @nature.com 🆙
✅Immune evasion through mitochondrial transfer in the tumour microenvironment
🎯Previously unknown mechanism of cancer immune evasion through mitochondrial transfer
👥 Dr. Hideki Ikeda
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...
Immune evasion through mitochondrial transfer in the tumour microenvironment - Nature
Mitochondria with mutations in their DNA from cancer cells can be transferred to T cells in the tumour microenvironment, which leads to T cell dysfunction and impaired antitumour immunity.
www.nature.com
March 22, 2025 at 5:30 PM
hhorinouchi.bsky.social
🔥 @cellpress.bsky.social 🆙
✅Extracellular vesicles (EV) from the lung pro-thrombotic niche drive cancer-associated thrombosis and mets via integrin β2
🎯Lung interstitial macrophages produce Integrin β2 small EVs
👥Dr. Serena Lucotti
#LCSM @oncoalert.bsky.social
www.cell.com/cell/fulltex...
Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2
Cancer-associated thrombosis is a leading cause of mortality. Lucotti et al. uncover the formation of a pro-thrombotic niche in the non-metastatic lung microenvironment that promotes thrombosis and me...
www.cell.com
March 22, 2025 at 5:29 PM
hhorinouchi.bsky.social
🔥 @natmedicine.bsky.social 🆙
✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC
🎯MRD preceded imaging DFS by a median of 4.7
🩸RaDaR MRD analysis
👥 Dr. Roy Herbst @drtomjohn.bsky.social
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...
March 22, 2025 at 5:28 PM
hhorinouchi.bsky.social
🔥 @cp-cancercell.bsky.social 🆙
✅Turning the kaleidoscope: Innovations shaping the future of clinical trial design
🎯Reshaped, prismatic vision of clinical trials combining different knowledge
👥Dr. Grégoire Marret @lilliansiu.bsky.social
@oncoalert.bsky.social
www.cell.com/cancer-cell/...
Turning the kaleidoscope: Innovations shaping the future of clinical trial design
Current clinical trials are based on rigid designs and drug-centric approaches that can stifle flexibility and innovation. With advances in molecular biology and technology, there is an urgent call to...
www.cell.com
March 22, 2025 at 5:26 PM
hhorinouchi.bsky.social
🔥 @natrevclinoncol.bsky.social 🆙
✅Utilizing ctDNA to discover mechanisms of resistance to targeted Tx in pts with mNSCLC
👥Dr. Sophie M. Ernst @drsanjaypopat.bsky.social @benjaminbessemd.bsky.social @christianrolfo.bsky.social
#LCSM @oncoalert.bsky.social #LiquidBiopsy
www.nature.com/articles/s41...
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials - Nature Reviews Clinical Oncology
Acquired resistance is a common occurrence among patients with oncogene-driven non-small-cell lung cancer receiving targeted therapies. Monitoring of circulating tumour DNA in liquid biopsy samples pr...
www.nature.com
March 22, 2025 at 5:25 PM
hhorinouchi.bsky.social
🔥 @cp-cancercell.bsky.social 🆙
✅Distinct CD8+ T cell dynamics associate with response to neoadj cancer immunotherapies
🎯Doublet regimen-specific transcriptional and clonal dynamics of tumor-reactive CD8+ T cells
👥Dr. Housaiyin Li
@oncoalert.bsky.social
www.cell.com/cancer-cell/...
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Li et al. analyze CD8+ T cells collected from HNSCC patients treated with neoadjuvant immunotherapies. They show that different combination immunotherapies modulate CD8+ T cell functional states throu...
www.cell.com
March 22, 2025 at 5:22 PM
hhorinouchi.bsky.social
🔥 Annals of Oncology @myesmo.bsky.social 🆙
✅Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology
🎯Balanced, patient-oriented trial designs are eagerly warranted
👥Dr. Gabriele Antonarelli
#LCSM @oncoalert.bsky.social
www.annalsofoncology.org/article/S092...
Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology
Randomized clinical trials represent the gold standard for the introduction of innovative therapies in medical oncology, and they provide the highest level of evidence to ascertain the clinical activi...
www.annalsofoncology.org
March 22, 2025 at 5:21 PM
hhorinouchi.bsky.social
🔥 @natmedicine.bsky.social 🆙
✅A B7H3-targeting antibody–drug conjugate (YL201) in advanced solid tumors: a phase 1/1b trial
🎯ORR ES-SCLC 63.9%, lung adenocarcinoma 28.6%, and lymphoepithelioma-like carcinoma 54.2%
👥Dr. Yuxiang Ma
#LCSM @oncoalert.bsky.social #ADC
www.nature.com/articles/s41...
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial - Nature Medicine
In a large-scale, international, multicenter, phase 1/1b trial, treatment of patients with advanced solid tumors with the B7H3-targeting antibody–drug conjugate YL201 was safe and showed preliminary c...
www.nature.com
March 22, 2025 at 5:20 PM
hhorinouchi.bsky.social
🔥 @jtoonline.bsky.social 🆙
✅CROWN👑5y: First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC
🎯HR 0.22 (95%CI: 0.13‒0.37), 5-year PFS was 63% (95% CI: 49–74) by lorlatinib
👥 Prof. Yi-long Wu
#LCSM @oncoalert.bsky.social
jto.org/article/S155...
First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study
Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, showed significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patie...
jto.org
March 22, 2025 at 5:19 PM
hhorinouchi.bsky.social
🔥 Journal of Clinical Oncology @ascocancer.bsky.social 🆙
✅LIBRETTO-001 final: Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer
🎯mOS 47.6 (pretreated pts), not reached (Tx-naïve)
👥 Dr. OliverGautschi
#LCSM @oncoalert.bsky.social @ascopost.bsky.social
ascopubs.org/doi/10.1200/...
Selpercatinib in <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up...
ascopubs.org
March 22, 2025 at 5:18 PM
hhorinouchi.bsky.social
🌟 @iaslc.bsky.social @jtoonline.bsky.social
🔥Recipients of TOP5️⃣REVIEWERS
1️⃣Dr. Paolo Bironzo
2️⃣Dr. Nicolas Girard
3️⃣Dr. William Evans
4️⃣ @hhorinouchi.bsky.social
5️⃣Dr. Voon Pei Jye
🎉Congratulations🎊
#LCSM @oncoalert.bsky.social
iaslc.bsky.social IASLC @iaslc.bsky.social · Mar 17
🏅 Cheers to the Top 5 Reviewers for #JTOCRR in 2024! 🏅 Your hard work drives lung cancer research.

👏Thank you to Paolo Bironzo, Nicolas Girard, William Evans, Hidehito Horinouchi, & Pei Jye Voon for your contributions to JTO CRR! 👏

🔹 Apply for the 2025 Reviewer Workshop: bit.ly/ReviewerWS
March 22, 2025 at 5:15 PM
hhorinouchi.bsky.social
🔥 International Journal of Clinical Oncology 🆙
✅Japan Society of Clinical Oncology position paper
🩸Molecular residual disease #MRD
👥 @Shin Kobayashi
😃Huge thanks to Drs. Takayuki Yoshino and Yoshiaki Nakamura, and great team.
@oncoalert.bsky.social #Liquidbiopsy
link.springer.com/article/10.1...
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing - International Journal of Clinical Oncology
Although the 5-year relative survival rates for resectable solid tumors have improved over the past few years, the risk of postoperative recurrence necessitates effective monitoring strategies. Recent...
link.springer.com
March 22, 2025 at 5:13 PM
hhorinouchi.bsky.social
🌟 #DiaryofanOncologyLeader
🎙️ @solangepeters.bsky.social
🎤Interviewer @drjnaidoo.bsky.social
☑️Maxims for Oncologists
1️⃣Find your sponsors
2️⃣Don't worry about negative feedbacks
3️⃣ Free from guiltiness
4️⃣Overcome imposter syndrome
@oncoalert.bsky.social
youtube.com/watch?v=i6fe...
Diary of an oncology leader: Episode 1 – Solange Peters
YouTube video by European Society for Medical Oncology (ESMO)
youtube.com
March 22, 2025 at 5:12 PM
hhorinouchi.bsky.social
🔥 @naturecancer.bsky.social 🆙
✅Hallmarks of artificial intelligence contributions to precision oncology
🎯Cancer prevention and diagnosis
🎯Optimizing current treatments
🎯Advancing new treatments by
👥Dr. Tian-Gen Chang
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s43...
Hallmarks of artificial intelligence contributions to precision oncology - Nature Cancer
Ruppin and colleagues overview recent research on the use of AI frameworks in precision oncology, describe ten hallmarks of their contributions across cancer detection, therapy optimization and treatm...
www.nature.com
March 22, 2025 at 5:10 PM
hhorinouchi.bsky.social
🔥 @natrevcancer.bsky.social 🆙
✅ALK in cancer: from function to therapeutic targeting
🎯Multipronged approach directed against pathways that sustain the persistence of ALK+ tumors
👥Dr. Claudia Voena
#LCSM @oncoalert.bsky.social @alkpositive.bsky.social
www.nature.com/articles/s41...
ALK in cancer: from function to therapeutic targeting - Nature Reviews Cancer
ALK genetic alterations drive various malignancies through aberrant tyrosine kinase activation, promoting oncogenic cell growth and survival. Here, Voena et al. outline recent advances in ALK oncogeni...
www.nature.com
March 22, 2025 at 5:09 PM
hhorinouchi.bsky.social
🔥 Annals of Oncology @myesmo.bsky.social 🆙
✅Efficacy assessment in phase I clinical trials: endpoints and challenges
🎯Multiple efficacy endpoints, beyond classic endpoints, have been proposed for efficacy assessment
👥Dr. M.A. Gouda
@oncoalert.bsky.social
www.annalsofoncology.org/article/S092...
Efficacy assessment in phase I clinical trials: endpoints and challenges
The scope of phase I clinical trials in oncology goes beyond the conventional safety evaluation–only objectives of these trials in other specialties. Rather, most first-in-human cancer trials have the...
www.annalsofoncology.org
March 22, 2025 at 5:07 PM
hhorinouchi.bsky.social
🔥 @naturerevdrugdisc.bsky.social 🆙
✅Tumour-agnostic kinase inhibitors
🎯Precision medicine paradigm that has successfully launched tumour-agnostic drug development
👥Drs. Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
@oncoalert.bsky.social
www.nature.com/articles/s41...
Tumour-agnostic kinase inhibitors - Nature Reviews Drug Discovery
Multiple tumour-agnostic kinase inhibitors have been approved that are clinically effective regardless of tumour location. This Review describes the origins of tumour-agnostic drug development, focusi...
www.nature.com
March 22, 2025 at 5:05 PM
hhorinouchi.bsky.social
🔥 Lung Cancer @myesmo.bsky.social 🆙
✅A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent NSCLC
🎯ORR 21% in PTK7-expressing, NSQ, EGFR wild NSCLC
👥 Prof. Byoung Chul Cho
✅NCT04189614
#LCSM @oncoalert.bsky.social
www.lungcancerjournal.info/article/S016...
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer
Lung cancer is the second most common form of cancer and the leading cause of cancer-related deaths worldwide, with global estimates at 2.2 million new diagnoses and 1.8 million deaths annually [1,2]....
www.lungcancerjournal.info
March 22, 2025 at 5:04 PM
hhorinouchi.bsky.social
🔥 @iaslc.bsky.social @jtoonline.bsky.social 🆙
🥰TOP10 reviewers for 2024
Dr. Jordi Remon
Dr. Dipesh Uprety
Dr. Molly Siu Ching Li
Dr. Kuan-Yu Chen
Dr. Junko Tanizaki
Dr. Tomer Meirson
Dr. Stephanie Saw
@hhorinouchi.bsky.social
Dr. Misako Nagasaka
Dr. Jean-Louis Pujol
#LCSM
jto.org/article/S155...
March 22, 2025 at 5:01 PM
hhorinouchi.bsky.social
🔥 @jtoonline.bsky.social 🆙
✅JCOG2007 (NIPPON): Gut Microbiota in Advanced NSCLC Receiving Chemo-ICI
🎯Differences in microbial diversity and specific bacterial genera were associated with prognosis and serious AEs
👥 Dr. Taiki Hakozaki
#LCSM @oncoalert.bsky.social
jto.org/article/S155...
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
Immunotherapy has transformed treatment for non-small cell lung cancer (NSCLC). However, reliable biomarkers for treatment selection remain scarce. Gut microbiota has emerged as a potential biomarker,...
jto.org
March 22, 2025 at 4:56 PM
hhorinouchi.bsky.social
🔥 @thelancet.bsky.social 🆙
✅HARMONi-2: Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer
🎯PD-L1 ≥1% HR 0.51 [95% CI 0.38–0.69], PD-L1 ≥50% HR 0.48 [0.29–0.79]
👥Dr. Anwen Xiong
#LCSM @oncoalert.bsky.social
thelancet.com/journals/lan...
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Ivonescimab significantly improved PFS compared with pembrolizumab in previously untreated patients with advanced PD-L1 positive non-small cell lung cancer. Therefore, ivonescimab might represent anot...
thelancet.com
March 22, 2025 at 4:55 PM